Urothelial Carcinoma
Urothelial Carcinoma
Advertisement
Emily MenendezUpper Tract Urothelial Carcinoma | May 21, 2024
The use of minimally invasive RNU is linked to improved median OS and 90-day mortality in octogenarian patients with UTUC.
Read More
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | May 21, 2024
Dr. Li provides commentary on the rationale, design, and impact of the MoonRISe-1 study for intermediate-risk NMIBC.
Emily MenendezAdvanced Urothelial Carcinoma | May 20, 2024
Previous studies have demonstrated the efficacy of postchemotherapy nivolumab with high-dose ipilimumab for metastatic UC.
Katie S. Murray, DO, MSUrothelial Carcinoma | May 16, 2024
The panel offers concluding thoughts on selection criteria for lymph node dissection in patients with low-grade UTUC.
Katie S. Murray, DO, MSUrothelial Carcinoma | May 16, 2024
The panel dissects a longitudinal follow-up of a multicenter study of UGN-101 as well as other 2024 AUA meeting data.
Katie S. Murray, DO, MSUrothelial Carcinoma | May 16, 2024
The panel considers how to best treat patients with low-grade UTUC who experience disease recurrence post-surgery.
Katie S. Murray, DO, MSUrothelial Carcinoma | May 16, 2024
The panel highlights nephron-sparing approaches as well as current treatment pathways for low-grade UTUC.
Katie S. Murray, DO, MSUrothelial Carcinoma | May 16, 2024
The panel provides a disease state overview of low-grade UTUC, including considerations for diagnosis, staging, and grading.
Katie S. Murray, DO, MSUrothelial Carcinoma | May 16, 2024
The panel engages in a discussion related to risk stratification in UTUC, including identification of high-risk patients.
Katy MarshallNon-Muscle Invasive Urothelial Carcinoma | May 14, 2024
The primary end point of the analysis of cohort B was 12-month disease-free survival.
Patrick Soon-Shiong, MDNon-Muscle Invasive Urothelial Carcinoma | May 10, 2024
Dr. Soon-Shiong provides an overview of the groundbreaking data related to nogapendekin alfa inbakicept for NMIBC.
Emily MenendezAdvanced Urothelial Carcinoma | May 8, 2024
Data on the type of treatment received in each line of therapy, as well as the attrition rates, were recorded.
Vikram M. Narayan, MDNon-Muscle Invasive Urothelial Carcinoma | May 7, 2024
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
Vikram M. Narayan, MDNon-Muscle Invasive Urothelial Carcinoma | May 7, 2024
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Guru P. Sonpavde, MDAdvanced Urothelial Carcinoma | May 20, 2024
Drs. Ambinder and Sonpavde provide an update for CheckMate 901, characterizing treatment benefit in responders.
Stephan Broenimann, MDUpper Tract Urothelial Carcinoma | May 7, 2024
Drs. Murray and Broenimann highlight and evaluation of urinary genomic profiling for detection and molecular staging of UTUC.
Yair Lotan, MDNon-Muscle Invasive Urothelial Carcinoma | May 7, 2024
Drs. Murray and Lotan review the development and validation of AI biomarkers to predict outcomes in BCG-treated NMIBC.
Yair Lotan, MDUpper Tract Urothelial Carcinoma | May 7, 2024
Drs. Murray and Lotan highlight a recent multicenter study featuring longitudinal follow-up of UGN-101 for UTUC.
Katy MarshallAdvanced Urothelial Carcinoma | May 5, 2024
Researchers found increased OS and PFS benefits when patients received nivolumab plus gemcitabine.
Emily MenendezMuscle Invasive Urothelial Carcinoma | May 5, 2024
New findings from the Nure-Combo trial examined the use of ABX with nivolumab followed by RC and adjuvant nivolumab.
Advertisement
Advertisement
Advertisement